DBV is a global biopharmaceutical company dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments.
DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.
DBV Technologies was founded in 2002 by Bertrand Dupont, Christophe Dupont & Pierre-Henri Benhamou. The company has close to 240 employees with global headquarters in Montrouge, France and a representative office in New York, New York.
DBV Technologies is focused on food allergies (milk and peanut), and pediatric allergies for which there are currently no effective treatments. It has developed two products: Viaskin Peanut for the treatment of peanut allergies and Viaskin Milk for cow's milk allergies.
DBV has developed a proprietary technology platform called Viaskin®, which is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system.
DBV is backed by Sofinnova Partners, Lundbeckfonden Ventures, InnoBio Fund, & ALK Abelló among others. The company went public on Apr 5, 2012, it's IPO valuation was unknown.